Locust Walk Insights

LOCUST WALK INSIGHTS

What is the Point of Point of Care?

After stops and starts, successes and disappointments, point-of-care diagnostic testing (POCT) has finally come of age. From its humble beginnings in the 1990’s, POCT has become a $16 billion market, delivering value to patients, caregivers and investors. As a...

Key trends impacting Japan partnering

Over the past years, I have had the fortune of participating in negotiations and ultimate deals between Western and Japanese biopharmaceutical companies. Doing deals is never easy, no matter the geography. However, it does seem that negotiating with Japanese companies...

Maximizing the Likelihood of Closing a Deal This Year

A few months ago, I posted a related article about deal timing titled ‘Maintaining Deal Momentum in the Summer Months’.  Now it is early August, and we are deep in the summer slowdown.  Many of us are enjoying the last stints of our summer holidays before returning to...

Why is Family Office money so hard to find for life science companies?

As an early advocate for the importance of the family office in the biotech financing landscape, I have learned from recent experience what many entrepreneurs already know.  Raising money from family offices is hard. While there are several challenges to attracting...

To Tax, or Not to Tax, That is the Question.

The first half of 2017 has been relatively strong for the medical technology space.  In the public sector, MedTech stocks have been performing well.  Many believe this stems from the potential permanent repeal of the Affordable Care Act and its associated medical...

Biotalk, Episode 4: Stuart Kliman, Vantage Partners

In this Episode of Biotalk, Locust Walk’s Vice President, Josh Hamermesh, spoke to Stuart Kliman (skliman@vantagepartners.com), Founder and Partner at Vantage Partners, a global management consulting firm that specializes in the areas of negotiation and relationship...

Q2 2017 Trends in Life Science Finance

Our Q2 report analyzes current trends of 2017, and how life science strategic deal activity has been performing in recent years. In this report you can find an overview and analysis of: Biopharma public indices Biopharma IPOs Deal activity for strategic partnership...

Helping to Ensure Success After the Deal

One of my favorite places to hang out in Tokyo is the Apple Store in the Ginza area.  It is a beautiful four-story venue, complete with a theater (where one can sit and receive non-stop sessions on all of Apple’s products) and, of course, the Genius Bar.  One of the...

The Best Buyers Are The Best Sellers

As it is often necessary to structure creative deals with deferred and/or ongoing value delivered to the seller, an important but frequently overlooked component of the deal process is to position your company as the ideal partner for the acquired asset. Recently, the...

Maintaining Deal Momentum in the Summertime

Fresh off Memorial Day Weekend, I had to face the reality that summer is here! When the kids are out of school, the regular schedules that we have enjoyed throughout the year become replaced by a multitude of summer camps, travels, and family fun. But as we know,...

Looking at Deal Value Beyond the Headlines

The press release is the public’s first (and oftentimes only) view into the details of a transaction.  However, while the press release is the victory lap of a transaction process, it rarely  provides the full details of the transaction.  Sure, it provides basic...

Companies are bought, because they are sold

Every entrepreneur hopes that if they build it, someday someone will come knocking at their door with a large check. But what does it take to get someone to knock on that door? And, how do you make sure your caller actually has a large check? Selling. Companies are...